Isolation and identification of metabolites of porfiromycin formed in the presence of a rat liver preparation

Journal of Pharmaceutical Sciences

Volumn 89, Issue 2, 2000, Pages 191-198

  Lang, Wensheng ^a   Mao, John ^a   Wang, Qin ^a   Niu, Chuansheng ^a   Doyle, Terrence W ^a   Almassian, Bijan ^a  

^a Vion Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXY 2 METHYLAMINO 7 AMINOMITOSENE; 2 METHYLAMINO 7 AMINOMITOSENE; BUFFER; CARBAMIC ACID; DRUG METABOLITE; PORFIROMYCIN; POTASSIUM DIHYDROGEN PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; DIASTEREOISOMER; DRUG ACTIVATION; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; LIVER; MASS SPECTROMETRY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

EID: 0033997467     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6017(200002)89:2<191::AID-JPS6>3.0.CO;2-1     Document Type: Article

References (32)

1. Iyer VN, Szybalski W. 1964. Mitomycin and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 145:55-58.
2. Weissbach A, Lisio A. 1965. Alkyaltion of nucleic acids by mitomycin C and porfiromycin. Biochemistry 4:196-200.
3. Schwartz HS, Sodergren JE, Philips FS. 1963. Mitomycin C: Chemical and biological studies on alkylation. Science 142:1181-1183.
4. Tomasz M, Lipman R, Chowdary D, Shimotakahara S, Veiro D, Walker V, Verdine GL. 1986. Reaction of DNA with chemical or enzymatically activated mitomycin C: Isolation and structure of the major covalent adduct. Proc Natl Acad Sec USA 83:6702-6706.
5. Tomasz M, Lipman R, Chowdary D, Pawlak J, Verdine GL, Nakanishi K. 1987. Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235:1204-1208.
6. Keyes SR, Rockwell S, Sartorelli AC. 1985. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 45:3642-3645.
7. Rockwell S, Keyes SR, Sartorelli AC. 1988. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiation Res 116:100-113.
8. Rockwell S, Hughes CS, Keyes SR, Sartorelli AC, Kennedy KA. 1993. Porfiromycin as an adjunct to radiotherapy in young and old mice. Experimental Gerontol 28:281-293.
9. Fracasso PM, Sartorelli AC. 1986. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 46:3939-3944.
10. Foley HT, Shnider BI, Gold GL, Matias PI, Colsky J, Miller SP. 1967. Phase I studies of porfiromycin (NSC-56410). Cancer Chemother Rep 51:283-293.
11. Loo RV, Vaitkevicius VK, Reed ML, Vaughn CB. 1967. Phase I trial of porfiromycin (NSC-56410). Cancer Chemother Rep 51:497-502.
12. Izbicki R, Al-Sarraf M, Reed ML, Vaughn CB, Vaitkevicius VK. 1972. Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses). Cancer Chemother Rep 56:615-624.
13. Grage TB, Weiss AJ, Wilson W, Reynolds V. 1975. Phase I studies of porfiromycin (NSC-56410) in solid tumors. J Surg Oncol 7:415-420.
14. Baker LH, Izbicki RM, Vaitkevicius VK. 1976. Phase II study of porfiromycin vs. mitomycin C utilizing acute intermittent schedules. Med Pediatr Oncol 2:207-213.
15. Panettiere FJ, Talley RW, Torres J, Lane M. 1976. Porfiromycin in the management of epidermoid and transitional cell cancer: A phase II study. Cancer Treat Rep 60:907-911.
16. Schwartz HS. 1962. Pharmacology of mitomycin C: III. In vitro metabolism by rat liver. J Pharmacol Exp Ther 136:250-258.
17. Tomasz M, Lipman R. 1981. Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry 20:5056-5061.
18. Kennedy KA, Sligar SG, Polomski L, Sartorelli AC. 1982. Metabolic activation of mitomycin C by liver microsomes and nuclei. Biochem Pharmacol 31: 2011-2016.
19. Pan S, Andrews PA, Glover CJ, Bachur NR. 1984. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 259:959-966.
20. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sugar SG, Sartorelli AC. 1984. Role of NADPH: cytochrome C reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 44: 5638-5643.
21. Pan S, Iracki T. 1988. Metabolites and DNA-adduct formation from flavoenzyme-activated porfiromycin. Mol Pharmacol 34:223-228.
22. Pan S. 1990. Porfiromycin disposition in oxygen-modulated P388 cells. Cancer Chemother Pharmcol 27:187-193.
23. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D. 1994. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54:3196-3201.
24. Pan S, Akman SA, Forrest GL, Hipsher C, Johnson R. 1992. The role of NAD(P)H:quinone oxidoreductase in mitomycin C-and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother Pharmacol 31:23-31.
25. Pan S, Forrest GL, Akman SA, Hu L. 1995. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res 55:330-335.
26. Roertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. 1992. The sensitivity of human tumor cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmacol 44:409-412.
27. Keyes SR, Rockwell S, Sartorelli AC. 1989. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. Cancer Res 49:3310-3313.
28. Kinoshita S, Uzu K, Nakano K, Shimizu M, Takahashi T, Matsui M. 1974. Mitomycin derivatives. 1. Preparation of mitosane and mitosene compounds and their biological activities. J Med Chem 14: 103-109.
29. Curry SH, Whelpton R. 1983. Drug metabolism. In: The manual of laboratory pharmacokinetics. New York: Wiley. pp 82-98.
30. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206-210.
31. Bloch W, Schlesinger MJ. 1973. The phosphate content of Escherichia coli alkaline phosphatase and its effect on stopped flow kinetic studies. J Biol Chem 248:5794-5805.
32. Moore HW. 1977. Bioactivation as a model for drug design bioreductive alkylation. Science 197: 527-532.